<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885649</url>
  </required_header>
  <id_info>
    <org_study_id>Pro20170000806</org_study_id>
    <secondary_id>NCI-2016-01113</secondary_id>
    <secondary_id>081604</secondary_id>
    <secondary_id>P30CA072720</secondary_id>
    <nct_id>NCT02885649</nct_id>
  </id_info>
  <brief_title>Enzalutamide Before Surgery in Treating Patients With Kidney Cancer</brief_title>
  <official_title>Pilot Study of the Blockade of Androgens in Renal Cell Carcinoma Using Enzalutamide (BARE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase 0 trial studies how well enzalutamide works before surgery in treating&#xD;
      patients with kidney cancer. Androgens are a type of hormone produced by the body that may&#xD;
      cause kidney tumors to grow. Anti-hormone therapy, such as enzalutamide, may lessen the&#xD;
      amount of androgens produced by the body and keep kidney tumors from growing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To investigate the effects of neoadjuvant enzalutamide on clear cell renal cell carcinoma&#xD;
      (ccRCC).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive enzalutamide orally (PO) daily for 90 days in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding unavailable&#xD;
  </why_stopped>
  <start_date type="Actual">December 5, 2017</start_date>
  <completion_date type="Actual">March 2, 2020</completion_date>
  <primary_completion_date type="Actual">March 2, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cell proliferation</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor apoptosis as measured by annexin</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) as assessed by Common Terminology Criteria for Adverse Events version 4</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Post-operative complications will be documented according to the Clavien-Dindo Classification System.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor size as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>AR expression measured in pre- and post-treatment tissue samples by immunohistochemistry (IHC)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Pre- and post-treatment ccRCC samples will be used to purify mRNA, construct cDNA, and perform qPCR to quantify expression of mRNA. IHC staining will be performed on ccRCC pre- and post-treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Genome-wide analysis of post-treatment tissue samples assessed by whole exome and RNA sequencing</measure>
    <time_frame>Up to 36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Intracrine androgen signaling levels of testosterone and dihydrotestosterone assessed in tissue</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Pre- and post-treatment tissue levels of testosterone and dihydrotestosterone will be compared to their respective serum levels to assess intracrine androgen signaling in ccRCC following enzalutamide treatment.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <condition>Stage I Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (enzalutamide, nephrectomy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive enzalutamide PO daily for 90 days in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (enzalutamide, nephrectomy)</arm_group_label>
    <other_name>ASP9785</other_name>
    <other_name>MDV3100</other_name>
    <other_name>Xtandi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (enzalutamide, nephrectomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nephrectomy</intervention_name>
    <description>Undergo partial or radical nephrectomy</description>
    <arm_group_label>Treatment (enzalutamide, nephrectomy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical T1N0M0 (=&lt; 7 cm) renal mass as measured on cross-sectional imaging (computed&#xD;
             tomography [CT] or magnetic resonance imaging [MRI])&#xD;
&#xD;
          -  Biopsy proven ccRCC&#xD;
&#xD;
          -  Tumor with androgen receptor (AR) expressed &gt;= 4580 copies/ug ribonucleic acid (RNA)&#xD;
&#xD;
          -  Can provide informed consent&#xD;
&#xD;
          -  Adequate hepatic function (&gt;= 1.5 x upper limit of normal [ULN]; patient's with&#xD;
             Gilbert's disease are not excluded)&#xD;
&#xD;
          -  Adequate renal function (estimated glomerular filtration rate [GFR] &gt; 40mL/min)&#xD;
&#xD;
          -  No evidence of metastatic disease on baseline imaging (chest x-ray [CXR] or chest CT,&#xD;
             abdominal CT or MRI)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior use of androgen deprivation including enzalutamide&#xD;
&#xD;
          -  Pregnant women or women who are of child bearing age who are not willing to use two&#xD;
             (2) forms of contraception during treatment with enzalutamide and for six (6) months&#xD;
             after treatment&#xD;
&#xD;
          -  Men must use adequate methods of contraception during and at least 3 months after&#xD;
             treatment if engaging in sexual activity with a female of child bearing age&#xD;
&#xD;
          -  Known hypersensitivity to enzalutamide&#xD;
&#xD;
          -  History of unprovoked deep vein thrombosis/pulmonary embolism (DVT/PE) in past twelve&#xD;
             (12) months&#xD;
&#xD;
          -  Inability to stop anticoagulants/antiplatelet therapy peri-operatively&#xD;
&#xD;
          -  History of seizure or any condition that may predispose to seizure (e.g., prior&#xD;
             cortical stroke or significant brain trauma)&#xD;
&#xD;
          -  History of loss of consciousness or transient ischemic attack within twelve (12)&#xD;
             months of enrollment&#xD;
&#xD;
          -  Any unstable, serious co-existing medical conditions including but not limited to&#xD;
             myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,&#xD;
             clinically evident congestive heart failure, or cerebrovascular accident within twelve&#xD;
             (12) months prior to screening&#xD;
&#xD;
          -  Known or suspected brain metastasis or active leptomeningeal disease&#xD;
&#xD;
          -  Current use of exogenous testosterone&#xD;
&#xD;
          -  Retroperitoneal/hilar adenopathy concerning for locally advanced disease&#xD;
&#xD;
          -  Metastatic RCC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Singer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers Cancer Institute of New Jersey</investigator_affiliation>
    <investigator_full_name>Eric A. Singer, MD, MA, MS, FACS</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

